课件:MM的整体治疗.ppt

  1. 1、本文档共171页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
课件:MM的整体治疗.ppt

* * * * * * * * * * * * * * * Panel A shows the time to disease progression on the basis of assessment by the investigators; the median time to progression was 24.0 months in the bortezomib group and 16.6 months in the control group (hazard ratio in the bortezomib group, 0.48). According to algorithmic analysis, the median time to progression was 20.7 months in the bortezomib group and 15.0 months in the control group (hazard ratio in the bortezomib group, 0.54; P0.001). Panel B shows overall survival after a median follow-up of 16.3 months. Median survival was not reached in either group. During that time, 45 patients (13%) in the bortezomib group and 76 patients (22%) in the control group died (hazard ratio in the bortezomib group, 0.61). * OS on an ITT basis after median follow-up of 36.7 mo (or 3 years). Median number of treatment cycles administered: 9 in VMP (50 weeks) versus 8 in MP (48 weeks). VMP arm had 35% reduction in death versus MP. Three y OS: 68 % versus 54% OS in patients who had received subsequent therapy Survival from start of second-line therapy for all patients receiving second-line therapy Survival from start of second-line therapy for all patients receiving novel agents Conclusion: by giving VMP upfront there were no more agressive relapses GIMEMA(VMPT-VT vs VMP):意大利MM工作组 PETHEMA/GEM(VMP vs VTP诱导,VT vs VP维持 ):西班牙骨髓瘤工作组,This study was undertaken in 63 Spanish centres between March, 2006, and October, 2008. * * 治疗流程 新药 诱导治疗 维持治疗 初诊MM 65 岁 N=255 随 机 MPT-T (n=129),4周/6疗程 马法兰 4mg/m2 d1-7 泼尼松 40mg/m2 d1-7 沙利度胺 100mg/d 持续直至疾病进展 MP (n=126),4周/6疗程 马法兰 4mg/m2 d1-7 泼尼松 40mg/m2 d1-7 Palumbo A et al. Lancet 2006; 367:825-831. 对于高龄的MM病人:口服 MPT是有效的一线治疗方案。 ≥PR ≥nCR 2年EFS 3年OS ≥3级AE MPT-T 76.0% 27.9% 54% 80% 48% MP 47.6% 7.2% 27% 64% 25% p值 0.0006 0.19 0.0002 Lancet 2006; 367: 825–31 Blood. 2011;118(22):5759-5766 NDMM ≥65ys Randamized Vel 1.3mg/m2 d1,4, 8, 11, 22, 25, 29, 32 Mel 9mg/m2 d1-4 Pred 60mg/m2 d1-4 Thal 50mg/d Induction, Q6w, cycles1-4 mainte

文档评论(0)

iuad + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档